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The Effects of Antipsychotic Quality
Reporting on Antipsychotic and
Psychoactive Medication Use
John R. Bowblis, Judith A. Lucas, and Christopher S. Brunt
Objective. The objective of this study is to examine how nursing homes changed their
use of antipsychotic and other psychoactive medications in response to Nursing Home
Compare’s initiation of publicly reporting antipsychotic use in July 2012.
Research Design and Subjects. The study includes all state recertiﬁcation surveys
(n = 40,415) for facilities six quarters prior and post the initiation of public reporting.
Using a difference-in-difference framework, the change in use of antipsychotics and
other psychoactive medications is compared for facilities subject to public reporting
and facilities not subject to reporting.
Principal Findings. The percentage of residents using antipsychotics, hypnotics, or
any psychoactive medication is found to decline after public reporting. Facilities subject to reporting experienced an additional decline in antipsychotic use (1.94 vs.
1.40 percentage points) but did not decline as much for hypnotics (0.60 vs. 1.21
percentage points). Any psychoactive use did not vary with reporting status, and the
use of antidepressants and anxiolytics did not change.
Conclusion. Public reporting of an antipsychotic quality measure can be an effective
policy tool for reducing the use of antipsychotic medications—though the effect many
only exist in the short run.
Key Words. Nursing home compare, public reporting, quality, antipsychotics,
psychoactive medications

Following the Food Drug Administration (FDA) approval of atypical antipsychotics in the late 1990s, the use of antipsychotic medications among nursing
home residents increased rapidly over the next 15 years. Many of these residents were receiving antipsychotics to manage behavioral and psychiatric
symptoms associated with dementia (Briesacher et al. 2005; Ofﬁce of Inspector General [OIG] 2011). This led to widespread off-label use of antipsychotics, often viewed as a form of “chemical restraint” (Hughes, Lapane, and Mor
1999). In the mid-2000s, it became evident that these medications could result
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in signiﬁcant negative health outcomes in persons with dementia.1 Subsequently, the FDA issued public health advisories cautioning that atypical antipsychotics (2005), and later all antipsychotics (2008), are associated with
increased risk of mortality in persons with dementia.
Even with the public health advisories of the FDA, the quantity of antipsychotic medication use is still a concern as the national rates of antipsychotic
use remain high (Kales et al. 2011). In March of 2012, the Centers for Medicare and Medicaid Services (CMS) launched a national initiative, the Partnership to Improve Dementia Care in Nursing Homes, in an attempt to reduce
the unnecessary use of antipsychotic medications, especially for nursing home
residents with dementia (CMS 2012, 2013). As part of this initiative, CMS distributed for public comment revised surveyor guidance related to antipsychotics, launched a website (https://www.nhqualitycampaign.org/), and began
public reporting new quality measures on antipsychotic medication use on the
Nursing Home Compare (NHC) website. The purpose of this initiative,
including the public reporting of antipsychotic quality, was to improve behavioral health care practices and reduce inappropriate use of antipsychotics.
The focus of this paper is the public reporting of antipsychotic use on the
NHC website. Since 2002, NHC has publically reported various measures of
nursing home quality, with the intent of allowing consumers to compare the
quality of nursing home care in their local area. By logging onto the NHC
website, consumers and administrators are able to search nursing homes
within a geographic area and compare their quality performance. Quality is
currently reported using a 5-star system, but data on speciﬁc quality measures
are also available, such as number of deﬁciencies, stafﬁng levels, ﬁnancial penalties, and a set of resident care quality measures.
NHC did not initially include antipsychotic use as a measure of quality.
Starting in July of 2012, CMS began publically reporting an antipsychotic
quality measure on NHC that attempts to approximate “inappropriate” use.2
This measure is also included in the calculations of the 5-star quality scores of
facilities. The public reporting of an antipsychotic quality measure should
reduce the use of antipsychotics in nursing homes subject to public reporting.
But one of the unintended effects is that nursing homes may substitute other
Address correspondence to John R. Bowblis, Ph.D., Department of Economics and Scripps
Gerontology Center, Miami University, 800 E. High St., Oxford OH 45056; e-mail:
jbowblis@miamiOH.edu. Judith A. Lucas, Ed.D. R.N., G.C.N.S.-B.C., is with the Caroline D.
Schwartz College of Nursing, Seton Hall University, South Orange, NJ. Christopher S. Brunt,
Ph.D., is with the Department of Finance and Economics, Georgia Southern University, Statesboro, GA.
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medications that have similar sedating properties for antipsychotics. This
paper studies this issue by examining the changes in the use of antipsychotics
and other psychoactive medications just prior to and after the period in which
NHC began publicly reporting the long-stay antipsychotic quality measure.

CONCEPTUAL MODEL
The purpose of public reporting is to inform consumers about quality of care,
allowing the consumers to better differentiate quality among providers, and
thus incentivize providers to compete on quality. Empirical evidence suggests
that the consumer response to public reporting of quality in nursing homes is
small in magnitude (Stevenson 2006; Werner et al. 2012). Although consumers seem to be less responsive to reported quality, a majority of nursing home
administrators regularly check quality scores on NHC and take actions to
improve quality based on reported scores (Mukamel et al. 2007). The perception of providers that consumers may respond to this public information and
the ability of providers to use this information to benchmark quality against
their peers is an important driver to improve quality, with public reporting
resulting in quality improvement in some reported measures (Mukamel et al.
2008; Werner et al. 2009; Grabowski and Town 2011).3 Administrators may
alter behavior more than consumers because some measures of quality
reported may be utilized in lawsuits or as marketing tools to support quality
claims (i.e., deﬁciency-free).
While there is evidence that nursing homes modestly improve quality
after public reporting in some reported dimensions, incentivizing one measure of quality can distort facility efforts to achieve other dimensions of quality, especially those dimensions of quality that receive less regulatory scrutiny
(McKie 1970; Baker 2002; Bowblis and Lucas 2012; Bowblis et al. 2012; Lu
2012). In the case of NHC, Lu (2012) examined the shift in deﬁciency citations
nursing homes received after the initial introduction of NHC. She found that
the number of deﬁciencies reported in domains (Quality of Life and Administration) not related to publically reported quality measures in NHC signiﬁcantly increased.
As this applies to the initiation of public reporting of the facility-level
antipsychotic quality measure by NHC, it is expected that public reporting
will have the intended effect of reducing the use of antipsychotic medications
more in nursing homes subject to public reporting. Also because of other
CMS efforts, it is expected that antipsychotic use would be lower in all
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facilities after the initiation of public reporting.4 However, because antipsychotic medications are often used to manage behavioral and psychiatric symptoms associated with dementia, and in some cases act as a “chemical restraint,”
nursing homes may offset this reduction in antipsychotic use by switching to
other medications that have similar sedative properties. These other medications, which include other psychoactive medications such as antidepressants,
anxiolytics, and hypnotics (Hughes and Lapane 2005), are highly prevalent in
nursing homes (Simoni-Wastila et al. 2014). This incentive to substitute may
be weakened if there is sufﬁcient regulatory and clinical burden to using these
alternatives. However, if substitution does occur, this does not address the
issue of managing dementia care, as many of these alternatives also have
harmful side effects and are associated with the same quality of life issues as antipsychotics (American Geriatrics Society 2012). Any signiﬁcant substitution
can lead to future, unintended public policy concerns.

M ETHODS
The primary source of data utilized in this study is the Certiﬁcation and Survey
Provider Enhanced Reports (CASPER). CASPER is CMS’s redesigned
reporting system and is the successor to the Online Survey, Certiﬁcation and
Reporting (OSCAR) System. Both OSCAR and CASPER contain data validated onsite by state surveyors during the annual recertiﬁcation process
required for nursing homes to be eligible for Medicare and Medicaid reimbursement. These surveys occur no less often than every 15 months, with the
average time between surveys of approximately 12 months, and data collected include characteristics on the facility and residents, aggregated to the
facility level. State surveyors review the data and conduct checks by comparing the facility report against individual resident records, stafﬁng records, and
observations of residents during the onsite visit, making this data valid for
research purposes (Feng et al. 2005).
Using the identiﬁcation number of the facility and the survey date, CASPER data are converted into a panel dataset where the unit of observation is a
nursing home survey. All state surveys from the 50 states and the District of
Columbia that occurred between January 1, 2011 and December 31, 2013 are
utilized.5 This period is chosen because it captures the state of the nursing
home industry six quarters before and after CMS initiated public reporting of
a long-stay antipsychotic quality measure in July of 2012. The ﬁnal dataset
contains 40,415 nursing home survey observations from 15,319 facilities.
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Using information in CASPER, six measures of medication utilization
are calculated. For each class of medication, the proportion of residents using
a medication is calculated by dividing the number of residents using that medication class by the number of residents in the facility. The measure reﬂects use
among all residents in the nursing home, both long- and short-stay residents.
Medication utilization measures are calculated for antipsychotics, hypnotics,
anxiolytics, antidepressants, and any psychoactive medication. Antibiotic use
is also calculated to serve as a robustness check and is described below. The
empirical strategy is to compare how the proportion of residents using psychoactive medications changes after public reporting was initiated.
Just comparing the pre-postdifferences in medication utilization rates
after public reporting leaves open the possibility that the ﬁndings are an artifact of some other unmeasured factor, such as the other CMS efforts to reduce
the use of antipsychotics or separate temporal trends. Therefore, we apply an
approach commonly used in the literature (Glickman et al. 2007; Lindenauer
et al. 2007; Werner et al. 2009; Konetzka et al. 2014) to identify a comparison
or control group (i.e., nonreporting nursing homes) that is either not affected
or impacted less by public reporting. This will allow for the identiﬁcation of
the effect of public reporting alone, but it should be noted that antipsychotic
utilization rates have been rather constant since 2005. Therefore, any reduction in antipsychotic utilization rates around the time of public reporting for
all facilities may be due to other CMS efforts described in the introduction.
The control group is identiﬁed using the antipsychotic quality scores for
long-stay residents from NHC obtained from CMS for the third quarter of
2012. This quarter reﬂects the ﬁrst quarter in which the measure was made
publically available. Nursing homes that do not have at least 30 residents for
calculating the quality measure are excluded from public reporting, and they
make up the control group of facilities that are not impacted by public reporting for this study (1,866 facilities). The control group is found to be rather similar in other characteristics to facilities subject to reporting other than number
of beds. In robustness checks, we ﬁnd that control group facilities behave similarly as nursing homes subject to public reporting, making them an ideal control group.
By comparing facilities subject to public reporting to facilities not subject
to public reporting, and examining the differences in how these facilities react
to public reporting, a difference-in-difference equation is estimated as:
Mit ¼ a1 Reportit þ a2 Postit þ a3 Report  Postit þ bXit þ di þ it
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where the Mit is a measure of medication utilization, Reportit is an indicator
variable if the facility is subject to public reporting of the antipsychotic quality
measure, Postit is an indicator for a survey after public reporting is initiated, Xit
are facility covariates, and di is a facility ﬁxed effect. The coefﬁcient estimate
of a3 identiﬁes the effect of public reporting. This coefﬁcient estimate reﬂects
the average change in utilization for the six quarters after public reporting
compared to the six quarters prior to public reporting among publically
reporting facilities compared to those that do not publically report. It may also
be the case that among facilities subject to public reporting that those with high
utilization of antipsychotics may respond differently to public reporting than
those with low utilization. Some regressions differentiate between these two
groups where high utilization is deﬁned as having over the median proportion
of long-stay residents using antipsychotics in the third quarter of 2012 (21.5
percent).
A consideration that must be addressed is how fast nursing homes can
react to public reporting as new medical plans need to be developed and medications withdrawn from residents. A pilot study found abrupt antipsychotic
discontinuation to be feasible (Azermai et al. 2013), but gradual dose reduction is recommended. Guidelines on how to taper dosages are unclear, but the
general goal is to wean individuals off antipsychotics in 4–6 weeks while alternatives to antipsychotics are tried (Gordon 2014). This implies that in the short
run, the effect of public reporting may be smaller as nursing homes initially
reduce dosage and ﬁnd alternatives to antipsychotics. To allow for this potential effect, the above equation is also estimated to allow for a short run and
longer run effect by breaking the post-implementation period into the three
quarters immediately following the initiation of public reporting (short run)
and the fourth to sixth quarters after public reporting (longer run).6
The advantage of the difference-in-difference approach is the effect of
the policy can be identiﬁed and any unmeasured factors that affect all facilities
are identiﬁed by the group of facilities not subject to public reporting. Furthermore, by including facility ﬁxed effects in the regression, any unmeasured factors that are ﬁxed over the study period are also accounted for in the
regression. Any other factors that may affect the utilization rate of medication,
such as facility structure, resident case mix, and stafﬁng resources are captured
in the facility control variable, Xit. The selection of these variables is guided by
the previous literature on appropriate prescribing and responses to nursing
home public reporting (Hughes, Lapane, and Mor 1999; Liperoti et al. 2003;
Lau et al. 2004; Mukamel et al. 2008; Werner et al. 2009).
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Although this approach has many advantages, a key assumption of the
difference-in-difference analysis, the common trend assumption, must hold.
As it applies in this case, absent public reporting, the trends in the proportion
of residents using a medication at facilities subject to and not subject to public
reporting should be the same. To test this assumption, regression models are
estimated to compare the trends in the utilization of each medication in the six
quarters prior to public reporting. These regressions did not ﬁnd statistically
signiﬁcant evidence that these trends were different and support the validity of
the difference-in-difference approach (results not shown).
Another validity check of this approach is to determine if a statistically
signiﬁcant effect is found for a medication that should not be affected by public
reporting. There is no clinical reason why attempting to reduce the use of antipsychotics should affect the utilization of antibiotics. Therefore, as an additional robustness check, the proportion of residents using antibiotic
medication is examined. The results are consistent with the difference-in-difference approach being valid. The results for these regressions are reported in
the tables, but they are not discussed.

RESULTS
Table 1 reports the average proportion of residents using various medications
for six quarters prior to and six quarters after the initiation of publically reporting the antipsychotic quality measure on NHC and the change in that proportion between the two periods. The proportions are reported for facilities that
were not required to report quality and for those required to report, stratiﬁed
by low- and high-use nursing homes. It should be noted that these proportions
reﬂect the actual reported proportions and are not adjusted for differences in
case mix or other characteristics.
Facilities required to report the antipsychotic quality measure had
higher antipsychotic use in the high-use facilities compared to low-use facilities in the period prior to public reporting (31.3 percent vs. 17.3 percent). Facilities not subject to reporting had 24.8 percent of residents using an
antipsychotic. During the public reporting period, all three groups of facilities
saw reductions in the proportion of residents using antipsychotic medications.
For nonreporting facilities, the decline averaged 0.87 percentage points. Facilities required to publically report quality saw greater declines. These ranged
from 1.89 percentage points for low-use and 1.61 percentage points for highuse facilities.
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Table 1: Unadjusted Medication Use Rate by Public Reporting Status

Antipsychotics
Nonreporting facilities
Low-use reporting facilities
High-use reporting facilities
Hypnotics
Nonreporting facilities
Low-use reporting facilities
High-use reporting facilities
Anxiolytics
Nonreporting facilities
Low-use reporting facilities
High-use reporting facilities
Antidepressants
Nonreporting facilities
Low-use reporting facilities
High-use reporting facilities
Psychoactives
Nonreporting facilities
Low-use reporting facilities
High-use reporting facilities
Antibiotics
Nonreporting facilities
Low-use reporting facilities
High-use reporting facilities

Average Rate:
Six Quarters Prior to
Public Reporting (%)

Average Rate:
Six Quarters Post
Public Reporting (%)

Difference
Post-Prior (%)

24.828
17.348
31.326

23.954
15.459
29.716

0.874
1.889
1.610

9.284
6.865
7.886

8.124
6.317
7.340

1.160
0.548
0.546

23.286
20.272
24.740

23.367
20.538
25.037

0.081
0.266
0.297

45.814
46.998
51.632

44.984
45.735
50.778

0.830
1.263
0.854

65.291
61.546
69.245

63.329
60.026
67.615

1.962
1.520
1.630

12.035
9.193
8.440

11.987
9.289
8.755

0.048
0.096
0.315

Note. The period prior to and post public reporting refers to the six quarters before and after July 1,
2012. The number of nonreporting, low-use reporting, and high-use reporting facilities are 1,866,
6,707, and 6,746, respectively.

For the other medications, the unadjusted proportion of residents using
hypnotics, antidepressants, and any psychoactive medication declined after
public reporting for all three groups of facilities (0.55 to 1.16, 0.83 to
1.26, 1.52 to 1.96 percentage points, respectively). Speciﬁcally for hypnotics, the size of the decline is about twice as large for nonreporting facilities
compared to facilities required to report quality. All facility groups saw an
increase in the proportion of residents using anxiolytics, with increases in the
range of 0.08 to 0.30 percentage points.
Adjusting for differences in case mix and other characteristics, Table 2
reports the difference-in-difference results, and full regression results are available in the online appendix. The ﬁrst column of the table reports the change in
the proportion using the speciﬁc class of medication for nonreporting facilities

All Reporting
Facilities
0.552* (0.308)
0.613** (0.248)
0.040 (0.412)
0.464 (0.472)
0.204 (0.523)
0.174 (0.341)

Nonreporting
Facilities

1.389*** (0.298)
1.213*** (0.268)
0.059 (0.367)
0.618 (0.488)
2.041*** (0.492)
0.012 (0.387)

0.614* (0.329)
0.618** (0.259)
0.095 (0.414)
0.574 (0.477)
0.416 (0.545)
0.050 (0.357)

Low-Use Reporting
Facilities
0.489 (0.317)
0.608** (0.248)
0.016 (0.437)
0.354 (0.511)
0.009 (0.538)
0.298 (0.351)

High-Use
Reporting Facilities

.5371
.9247
.6157
.3950
.1614
.1304

Test for Difference
between Low and
High Use (p-value)

Note. Change in pre-post is calculated using a difference-in-difference regression design. Regressions also control for ownership, chain membership, part
of a CCRC, facility size, occupancy rate, payer mix, physical acuity, mental health acuity, presence of Alzheimer’s special care unit, nurse stafﬁng levels,
presence of mental health services, physician model, and facility ﬁxed effects. All standard errors are adjusted for clustering within the state. The sample
size is 40,415 observations.
†
Additional change reﬂects the additional change in post period for facilities publically reporting antipsychotic quality relative to facilities not reporting.
The All column is the total effect for all facilities publically reporting quality, whereas Low- and High-use columns differentiate facilities based on the
level of antipsychotic use. The Difference (p-value) column reports the p-value to determine if there is a difference in the change for low- compared to
high-use reporting facilities.
***p < .01, **p < .05, *p < .10.

Antipsychotics
Hypnotics
Anxiolytics
Antidepressants
Psychoactives
Antibiotics

Dependent Variables:
Percentage of
Residents Using

Additional Change for Reporting Facilities†

Table 2: Change in Medication Use Prior and after Public Reporting of Antipsychotic Quality Measures
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prior to and after public reporting. The next three columns report the additional change after public reporting for all, low-use, and high-use facilities subject to reporting. The ﬁnal column reports the p-value of F-test to determine if
the change for low compared to high use is statistically different from each
other.
The regressions in Table 2, which compare the six quarters prior to and
after the initiation of public reporting, conﬁrm the summary statistic results
reported in Table 1. For antipsychotics, all facilities experienced a decline in
the use of antipsychotics, with a larger decline for facilities subject to public
reporting. For nonreporting facilities, the decline averaged 1.40 percentage
points and for all facilities subject to reporting, the decline was 1.94 percentage
points. The difference between the two groups is statistically signiﬁcant. While
the decline for high-use facilities is slightly smaller than low use (total decline
of 1.88 vs. 2.00 percentage points), the difference is not statistically signiﬁcant.
In the case of hypnotic medications, nonreporting facilities experienced
a decline of 1.21 percentage points compared to a decline of 0.60 percentage
points for facilities subject to reporting. The use of any psychoactive medication is found to decline after public reporting by 2.04 percentage points, but
there is no statistical difference by reporting status. Though the direction of
the coefﬁcient estimates for anxiolytics and antidepressants is consistent with
the results found in Table 1, there are no statistically signiﬁcant changes in the
use of these medications.
One disadvantage of using the approach in Table 2 is it compares the
average effect for the six quarters prior to and after the initiation of public
reporting. One might expect that the reactions of public reporting may take
some time. In Table 3, the effect of public reporting in the postperiod is differentiated into the short and longer run, for all facilities required to report
regardless of use. For antipsychotics, the short run ﬁnds facilities subject to
public reporting reduce the use of antipsychotics more than those that were
not subject to public reporting by an additional 0.87 percentage points. However, in the longer run, the difference is only an additional 0.16 percentage
points. Hypnotics are found to increase in facilities subject to reporting (0.52
percentage points) relative to those not reporting, but the effect is not statistically signiﬁcant until the longer run (0.73 percentage points). Public reporting
facilities have lower antidepressant use in the short run, but higher in the
longer run. Public reporting is not found to not have a statistically signiﬁcant
effect in the short or longer run for all other medications.
The results in Table 3 are conﬁrmed in Figures 1 and 2, which graphically show the adjusted trends in medication use after the implementation of
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Table 3: Short versus Longer Run Effects of Public Reporting
Short Run (Quarters 1–3
after Public Reporting)
Dependent
Variables:
Percentage of
Residents Using

Nonreporting
Facility Trend

Antipsychotics
Hypnotics
Anxiolytics
Antidepressants
Psychoactives
Antibiotics

Longer Run (Quarters 4–6
after Public Reporting)

Nonreporting
Facility Trend

Additional
Change
for Reporting
Facilities

1.844*** (0.460)
1.541*** (0.361)
0.302 (0.436)
0.239 (0.672)
0.893 (0.654)
0.254 (0.489)

0.157 (0.434)
0.727** (0.341)
0.145 (0.459)
0.550 (0.538)
0.724 (0.668)
0.001 (0.423)

Additional Change for
Reporting Facilities

1.035*** (0.279)
0.968*** (0.308)
0.112 (0.529)
1.182** (0.529)
2.846*** (0.649)
0.215 (0.377)

0.867*** (0.345)
0.517 (0.312)
0.035 (0.581)
1.225* (0.712)
0.168 (0.694)
0.314 (0.361)

Note. Change in pre-post is calculated using a difference-in-difference regression design that allows
for the post period to be in the short and longer run. The short run is the ﬁrst three quarters after
the initiation of public reporting and the longer run is four to six quarters after the initiation of public reporting. All regressions also control for ownership, chain membership, part of a continuing
care retirement community (CCRC), facility size, occupancy rate, payer mix, physical acuity,
mental health acuity, presence of Alzheimer’s special care unit, nurse stafﬁng levels, presence of
mental health services, physician model, and facility ﬁxed effects. All standard errors are adjusted
for clustering within the state. The sample size is 40,415 observations.
***p < .01, **p < .05, *p < .10.

Figure 1:

Trends after Reporting: Antipsychotics

1.05
1
0.95
0.9
0.85
0.8
0.75
Baseline

Q3 2012

Q4 2012

Q1 2013

Non-Reporting

Q2 2013

Q3 2013

Q4 2013

Reporting

Note. To construct this ﬁgure, the difference-in-difference regression is estimated allowing for the
effect after public reporting to vary with the quarter after public reporting. The baseline period is
the average proportion of residents using the medication in the six quarters prior to public reporting and is indexed to the value 1. Any number under 1 indicates a decline in the proportion of residents using that medication relative to the baseline period. Therefore, a value of 0.95 indicates for
that group of facilities, the reported outcome is 95 percent of the level it was at baseline.
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Figure 2:

Trends after Reporting: Hypnotics

1.05
1
0.95
0.9
0.85
0.8
0.75
Baseline

Q3 2012

Q4 2012

Q1 2013

Non-Reporting

Q2 2013

Q3 2013

Q4 2013

Reporting

Note. To construct this ﬁgure, the difference-in-difference regression is estimated allowing for the
effect after public reporting to vary with each quarter after public reporting. The baseline period is
the average proportion of residents using the medication in the six quarters prior to public reporting and is indexed to the value 1. Any number under 1 indicates a decline in the proportion of residents using that medication relative to the baseline period. For example, a value of 0.95 indicates
for that group of facilities, the reported outcome is 95 percent of the level it was at baseline.

public reporting for the two classes of medications for which public reporting
is found to have a statistically signiﬁcant effect—antipsychotics and hypnotics.
In both ﬁgures, the reporting and nonreporting facilities’ use of medications
for the six quarters prior to public reporting (baseline) are indexed to 1. This
allows for comparison of the rate of utilization after public reporting compared to the prereporting period, with values less than 1 implying that overall
utilization rates have declined. For example, a value of 0.95 would imply utilization rates 95 percent of what they were in the baseline period.
The use of antipsychotic medications for nonreporting and reporting
facilities declined in the six quarters after public reporting was initiated. The
use of antipsychotics declined faster for reporting facilities and remained high
for nonreporting facilities until about the ﬁrst quarter of 2013. Starting in the
second quarter of 2013, the declines in antipsychotic use for both groups were
about the same, but became larger for nonreporting in the last two quarters of
2013. In contrast, the decline from baseline in the use of hypnotics is larger for
nonreporting facilities for all six quarters after the implementation of public
reporting. Interestingly, the average decline becomes almost the same for both
groups in the fourth quarter of 2013.
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DISCUSSION
The effort to improve quality through public reporting of an antipsychotic
quality measure is found to have the intended effect of reducing the use of antipsychotic medications in the short run. While all facilities saw a reduction in
the use of antipsychotics, facilities subject to public reporting saw declines in
the proportion of residents using antipsychotics that were about 40 percent
larger than facilities not subject to reporting. The size of the clinical effect is
rather large and represents over 6,800 fewer residents receiving antipsychotics
on a given day. Given the costs of these medications and that these drugs lead
to 1 to 2 additional deaths per 100 persons (Schneider, Dagerman, and Insel
2005), the beneﬁts of reducing antipsychotic use is rather large relative to the
risk of continued use.
Though public reporting is having the intended effects, the differencein-difference analysis does not tell the entire story. Early after NHC public
reporting, antipsychotic use remained relatively level in nonreporting facilities and then started to decline steadily following the second quarter of 2013.
By the last quarter of 2013, nonreporting facilities saw similar declines in the
proportion of residents using antipsychotic medications to those facilities subject to public reporting. This pattern is consistent with public reporting incentivizing reporting facilities to initially act faster, but all facilities eventually
experience similar decreases in the use of antipsychotics.
This is similar to the pattern found in physical restraints. In the late
1990s, there was a push to reduce the use of physical restraints and a physical
restraint quality measure was publically reported starting in 2002. Initially,
facilities that were subject to public reporting had a stronger incentive to
reduce the use of physical restraints; however, the initiation of public reporting the use of physical restraints has declined in all nursing homes (Konetzka
et al. 2014). Given our results only examine the six quarters after the initiation
of public reporting, additional analysis with more recent data will be required
to determine if antipsychotics follow the same long-term pattern found in the
use of physical restraints.
These results suggest that public reporting may have the intended effect
to incentivize facilities subject to reporting to fast-track speciﬁc quality
improvement efforts. In the longer term, the combined efforts of the
various CMS initiatives may have a similar impact on reducing the use of
antipsychotics among all nursing homes regardless of reporting status. By
stimulating nursing home staff and administrators to be aware of prescribing
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quality, public reporting of antipsychotic use may work by changing the culture of prescribing over time in all nursing homes (Hughes and Lapane 2005).
Public reporting is an attempt to improve processes of care, which has already
been found to be successful in reducing restraints.
All facilities are found to reduce the use of hypnotics. This is unexpected
because hypnotics have similar sedative properties as antipsychotics, and if
facilities are pressured to reduce the use of antipsychotics, they may switch to
using hypnotics. Some substitution is found to be present as facilities subject to
public reporting are found to decrease the use of hypnotics at a slower rate
than facilities not subject to public reporting. In fact, the effect sizes for public
reporting are similar, though in opposite directions for antipsychotics and
hypnotics. A potential reason for this pattern is substitution to an alternative
that is perceived as safe will occur, but substitution may occur to a lesser extent
if the alternative faces clinical and/or regulatory scrutiny.7 Hypnotics faced
this scrutiny as CMS changed regulatory guidelines related to antipsychotics
and benzodiazepines starting in 2007 (CMS 2006) and hypnotics are known
to cause serious adverse drug reactions (American Geriatrics Society 2012).
The empirical result found in this paper may indicate CMS efforts have positive externalities to other medications, but additional investigation is warranted that uses resident-level data.
Our results should be interpreted with some caution. First, the results
are based on facility-level and drug class data. By using individual residentlevel clinical and drug data, the case mix and the speciﬁc agent(s) used by the
resident could be identiﬁed. This would allow restricting the study population
to residents with dementia and identify which psychoactive medications are
being substituted for antipsychotics. Nonetheless, our data provide for the
identiﬁcation of general trends in the number of residents using antipsychotic
and other psychoactive medications while controlling for facility-level case
mix. Second, facilities not subject to reporting are smaller than the typical
nursing home. As a robustness check, facilities of similar size were compared
by restricting the sample to smaller facilities. These results were found to be
robust, and in some cases, stronger than the ones reported. Finally, NHC
reports separate antipsychotic quality measures for short-stay residents at the
same time as long-stay residents. These two measures are found to be highly
correlated, and many facilities subject to reporting for one measure are subject
to reporting for the other. The effects of each of these measures need to be
investigated using resident-level data that are restricted to the length of stay of
the resident.
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CONCLUSION
While most studies ﬁnd little effect of public reporting on quality, and only in
select measures (Mukamel et al. 2008; Werner et al. 2009; Grabowski and
Town 2011), this study ﬁnds that public reporting of an antipsychotic quality
measure can be an effective policy tool for reducing the use of antipsychotic
medications in the short run. Though the absolute effect of public reporting is
rather small, the clinical beneﬁts are large given the high risk and limited beneﬁt of antipsychotic use in nursing homes. It should be noted that this effect
may only exist in the short run. In the long run, the effect of public reporting
may not be sufﬁcient alone but may need to be combined with other strategies,
such as antipsychotic-speciﬁc deﬁciencies and ﬁnancial penalties. These other
strategies provide pressure to nursing homes to reduce the use of antipsychotic
medications and provide CMS another mechanism to stimulate care process
improvement. These other strategies may not be effective alone as public
reporting would allow nursing homes to benchmark how their performance
compares to peers. Therefore, there is still a role for public reporting even if
the effects are small and become negligible in the longer run, as the public
information provides nursing home administrators and policy makers benchmarks to identify the progress of all initiatives to reduce antipsychotic medications.
However, public reporting may have unintended consequences as
nursing homes substitute care practices that face less regulatory scrutiny.
While all facilities reduce the use of psychoactive medications in general,
our ﬁnding that facilities subject to reporting reduced use of hypnotics
more slowly may be consistent with some facilities substituting drugs that
are not publically reported but with similar sedative properties as antipsychotics. We caution that while our study provides preliminary evidence
that this form of substitution may already be occurring, it does not provide absolute proof and further research is needed to explore this issue.
In conclusion, public reporting of quality performance by itself seems to
have a limited but positive role in improving quality (Werner et al. 2009).
When combined with other strategies, it may be an effective mechanism
enhancing other quality improvement efforts. However, policy makers need
to be watchful for unintended consequences as nursing homes may switch to
unreported care practices that may also cause harm. Either way, the effect of
quality reporting on NHC and other CMS initiatives to reduce the use of antipsychotic medications overall seem to be having the intended impact.
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NOTES
1. These health outcomes include movement disorders, falls, hip fractures, infections,
strokes, and increased risk of death (Schneider, Dagerman, and Insel 2005, 2006b;
Schneider, Tariot, and Dagerman 2006a; Rochon et al. 2008; Ray et al. 2009;
Huybrechts et al. 2012).
2. The measure used by NHC is the percent of nursing home residents who are receiving
an antipsychotic medication, excluding those residents diagnosed with schizophrenia,
Huntington’s disease, or Tourette’s syndrome (CMS, 2012). There is some debate as
to whether this measures captures only “inappropriate” use (Lucas et al. 2014).
3. For example, Mukamel et al. (2008) examined ﬁve different publically reported measures but only found improvement in two—physical restraints and pain for short-stay
residents. Werner et al. (2009) examined reporting of quality for postacute care and
found improvement in two of three NHC measures—pain and improved walking.
Finally, Grabowski and Town (2011) found very little evidence to suggest NHC
resulted in better long-stay quality, but nursing homes in more competitive markets
improved reported quality more than those in less competitive markets.
4. The use of antipsychotic medications has been relatively constant in nursing homes
since 2005.
5. Some surveys from the fourth quarter of 2013 may be missing in the CASPER data
utilized in the study. The CASPER data reﬂect all completed state surveys available
as of December 2013, and because of slow upload times to the database, some surveys may not have been uploaded at the time the data were obtained.
6. The variable Postit in the equation above is replaced with two indicator variables
that identify the short and longer run.
7. This is consistent with the ﬁndings of Konetzka et al. (2014), which show that the
substitution of physical restraints for antipsychotics seems to end after the safety of
atypical antipsychotic medications started to be questioned in 2005 (see Figure 3 in
their paper).
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